Pay in 4 interest-free payments of $5.38 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Bowling Green, KY was even dubbed Ozempictown, USA given how many prescriptions were filed in the state
Injectable Pen Segment is Expected to Drive the GLP-1 Drug Biosimilar Market The market share of the Injectable Pen segment was the largest in 2025
Yammine et al
The Advisory Committee did not review the use of once-weekly insulin icodec for type 2 diabetes
If you see these patterns in any GLP-1 telehealth platform's marketing, they are the exact claims FDA has called misleading: Calling compounded semaglutide or tirzepatide a "generic" version of Ozempic or Wegovy - compounded drugs are not FDA-approved generics Implying FDA approved or reviewed the compounded product for safety, effectiveness, or quality - the FDA hasn't Claiming the pharmacy is "FDA-approved" or "FDA-licensed" - FDA registers facilities but does not "approve" or "license" compounding pharmacies in the way that phrase implies Branding compounded medication with the telehealth company's name in a way that suggests the telehealth company is the compounder - they're not Any messaging that implies the compounded product is "clinically proven" to perform the same as the FDA-approved branded drug This article avoids all of those patterns
